CagriSema vs Leuphasyl
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →Leuphasyl
Leuphasyl (Pentapeptide-18) is a cosmetic peptide that reduces muscle tension through a mechanism similar to enkephalins. Often combined with Syn-Ake for enhanced anti-wrinkle effects.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | Leuphasyl |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Mimics enkephalin and binds to enkephalin receptors on muscle cells, reducing acetylcholine release and thereby decreasing muscle contraction intensity. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Topical: 3-8% concentration in serums. Often used in combination products with other muscle-relaxing peptides. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Topical application to expression lines. Best results with consistent twice-daily use over 8+ weeks. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | Very well-tolerated topically. No significant adverse effects reported at cosmetic concentrations. |
| Best For |
Key Differences
Unique to CagriSema:
Unique to Leuphasyl:
Detailed Analysis
Commonalities
CagriSema and Leuphasyl are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose CagriSema for Weight Loss, Diabetes Management. Choose Leuphasyl for Skin Health & Aesthetics.
Ready to Learn More?
Looking for trusted sources?